All In Biotech

Drug Trial Radar · NCT07899905

A Clinical Study of MK-7962 in Chinese Participants With Pulmonary Arterial Hypertension (MK-7962-022)

An Open-Label, Single-Arm, Multi-Center, Post-Marketing Study to Evaluate the Efficacy and Safety of Sotatercept (MK-7962) Add-on to Background Therapy in Chinese Participants With Pulmonary Arterial Hypertension (PAH)

Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Nov 30, 2026

Primary completion

Mar 21, 2028

Study completion Mar 21, 2028

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Oct 28, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers are looking for ways to treat people with a type of high blood pressure in the lungs called pulmonary arterial hypertension (PAH). This study focuses on Chinese participants who are already taking stable, standard-of-care medications for their PAH. Researchers want to know if adding the study treatment, sotatercept, to their current background treatment can help treat people with PAH. Participants in this study will start a new treatment regimen where they will receive sotatercept as an add-on therapy, and researchers will monitor their health. The main goals of this study are to learn if sotatercept is safe, if participants tolerate it well, and how effective it is at improving their exercise capacity and physical health when added to their ongoing PAH treatment.

Conditions

  • Hypertension, Pulmonary

Interventions

  • SotaterceptBiological

    subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in the 6-Minute Walk Distance (6MWD) at Week 24.Time frame: Baseline and Week 24
  2. Number of Participants Who Experience an Adverse Event (AE)Time frame: Up to approximately 37 weeks.
  3. Number of Participants Who Discontinue Study Treatment Due to an AETime frame: Up to approximately 21 weeks.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.